In today’s session Shire PLC (ADR) (SHPG) recorded an unusually high (223) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious SHPG decrease. With 223 contracts traded and 364 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: SHPG161021P00187500 closed last at: $2 or 7% down. About 356,891 shares traded hands. Shire PLC (ADR) (NASDAQ:SHPG) has risen 20.67% since March 4, 2016 and is uptrending. It has outperformed by 12.64% the S&P500.
Analysts await Shire PLC (ADR) (NASDAQ:SHPG) to report earnings on October, 28. They expect $3.14 earnings per share, down 3.09% or $0.10 from last year’s $3.24 per share. SHPG’s profit will be $940.98 million for 15.41 P/E if the $3.14 EPS becomes a reality. After $3.38 actual earnings per share reported by Shire PLC (ADR) for the previous quarter, Wall Street now forecasts -7.10% negative EPS growth.
Shire PLC (ADR) (NASDAQ:SHPG) Ratings Coverage
Out of 18 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 15 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 83% are positive. Shire plc (ADR) has been the topic of 28 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Credit Suisse upgraded the stock to “Outperform” rating in Tuesday, January 12 report. On Friday, May 20 the stock rating was maintained by JP Morgan with “Overweight”. On Friday, June 3 the stock rating was reinitiated by Morgan Stanley with “Overweight”. The firm earned “Outperform” rating on Tuesday, November 17 by Leerink Swann. The stock of Shire PLC (ADR) (NASDAQ:SHPG) has “Overweight” rating given on Monday, September 21 by Barclays Capital. The firm has “Sector Perform” rating given on Monday, October 26 by RBC Capital Markets. Liberum Capital initiated the stock with “Buy” rating in Friday, May 6 report. The firm has “Buy” rating by Goldman Sachs given on Tuesday, June 28. As per Tuesday, January 12, the company rating was maintained by RBC Capital Markets. The firm earned “Buy” rating on Tuesday, October 27 by HSBC.
According to Zacks Investment Research, “Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)”
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The company has a market cap of $57.99 billion. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 30.73 P/E ratio.
SHPG Company Profile
Shire plc, incorporated on January 28, 2008, is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.
More recent Shire PLC (ADR) (NASDAQ:SHPG) news were published by: Businessfinancenews.com which released: “Shire PLC (ADR) Future Now Rests On Xiidra” on July 12, 2016. Also Businessfinancenews.com published the news titled: “Shire PLC (ADR): Geared up to Inflate Drug Assortment” on June 21, 2016. Businessfinancenews.com‘s news article titled: “Shire Goes Deeper into Hemophilia Segment” with publication date: August 01, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.